The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | ESMO 2018 Congress
Videos  >  

Immunotherapy Enters the Treatment Landscape for Cervical Cancer

Krishnansu S. Tewari, MD
Published Online:3:53 PM, Wed October 10, 2018


Krishnansu S. Tewari, MD, associate professor, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of California, Irvine, discusses the excitement around immunotherapy in cervical cancer. 

Scientifically, it makes sense to look at these therapies in this setting, Tewari says. The mutational burden of cervical cancer is similar to other solid tumors where immunotherapy has had positive results, according to phase III findings. 

Similar tumor clusters in certain lung cancers and head and neck cancers have shown a signal for immunotherapy, especially with checkpoint inhibition. Cemiplimab (Libtayo), an anti-PD-1 agent, is now under investigation in patients with cervical cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.